Table 1.
Characteristics of the PROSISA cohort
| Males, N (%) | 8699 (52.1%) |
| Age [years], mean (SD) | 60.5 (12.0) |
| BMI [kg m−2], mean (SD) | 27.3 (4.5) |
| Systolic blood pressure [mmHg], mean (SD) | 131.3 (16.4) |
| Diastolic blood pressure [mmHg], mean (SD) | 78.8 (9.7) |
| Physical activity, N (%) | 2602 (24.4%) |
| Smoking status, N (%) | |
| Never | 7630 (52.2%) |
| Former | 4277 (29.2%) |
| Current | 2720 (18.6%) |
| Hypertension, N (%) | 8345 (57.3%) |
| Type 2 diabetes mellitus, N (%) | 3439 (24.4%) |
| Any previous cardiovascular event, N (%) | 5234 (38.0%) |
| Ischaemic heart disease, N (%) | 2581 (19.5%) |
| Peripheral arterial disease, N (%) | 3297 (24.5%) |
| Chronic kidney disease, N (%) | 1165 (9.0%) |
| Significant liver disease, N (%) | 765 (6.1%) |
| Total cholesterol [mg dL−1], mean (SD) [mmol L−1, mean (SD)] | |
| Pretreatment | 281.6 (60.2) [7.3 (1.6)] |
| On‐treatment | 192.1 (44.4) [5.0 (1.1)] |
| LDL cholesterol [mg dL−1], mean (SD) [mmol L−1, mean (SD)] | |
| Pretreatment | 191.7 (54.6) [5.0 (1.4)] |
| On‐treatment | 111.1 (38.3) [2.9 (1.0)] |
| HDL cholesterol [mg dL−1], mean (SD) [mmol L−1, mean (SD)] | |
| Pretreatment | 54.3 (16.4) [1.4 (0.4)] |
| On‐treatment | 53.8 (16.0) [1.4 (0.4)] |
| Triglycerides [mg dL−1], median (IQR) [mmol L−1, median (IQR)] | |
| Pretreatment | 147.0 (102.0–225.0) [1.7 (1.2–2.5)] |
| On‐treatment | 118.0 (86.0–166.0) [1.3 (1.0–1.9)] |
| Statin treatment at baseline, N (%; mean dose [mg day−1]) | |
| Simvastatin | 5285 (31.9%; 21.2) |
| Atorvastatin | 5278 (31.8%; 20.6) |
| Rosuvastatin | 4522 (27.2%; 12.1) |
| Pravastatin | 856 (5.2%; 27.3) |
| Fluvastatin | 419 (2.5%; 75.5) |
| Lovastatin | 234 (1.4%; 21.2) |
| High‐intensity statin therapy, N (%) | 4337 (26.2%) |
| Other lipid‐lowering treatments, N (%) | 4218 (25.2%) |
| Potential statin interacting drugs, N (%) | 1091 (6.5%) |
BMI, body mass index; IQR, interquartile range.